Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor (Nasdaq: DXR), a leader in blood volume measurement technology, reported significant growth in its mid-year update for 2024. Key highlights include:
1. Net Asset Value (NAV) increased to $6.75 per share from $6.33 last year.
2. Unaudited revenue for the first half of 2024 more than doubled compared to 2023.
3. Added 14 new accounts, surpassing the 12 added in 2023.
4. Reduced net cash investment to $1.297 million from $2.445 million in H1 2023.
5. Secured $2.45 million in government contracts for technology development.
6. Acquired Volumex®, Megatope®, and Glofil® to improve margins and expand product offerings.
7. Expecting operational positive cash flow by Q4 2024.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
CEO and President Michael Feldschuh will deliver a presentation, which will be available on-demand starting September 9, 2024, at 7:00 AM ET. Investors can register for the conference to access the presentation. Additionally, Mr. Feldschuh will be available for one-on-one meetings with registered investors at the conference venue.
Interested investors can contact Bret Shapiro at CORE IR by calling 1-516-222-2560 or emailing brets@coreir.com for more information or to schedule meetings.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced the expansion of its Blood Volume Analysis (BVA) technology. A 339-bed community hospital in northwest Mississippi, part of the Mid-South's largest integrated delivery network, has acquired a BVA analyzer for outpatient heart failure care. This acquisition is expected to enhance patient outcomes in a region with access to specialized care and accelerate sales growth for Daxor.
The move is particularly significant given Mississippi's high heart disease death rate of 324.4 per 100,000 people, compared to the national average of 173.8. Daxor's BVA diagnostic provides 98% accurate actionable data to guide fluid management decisions, enabling personalized care plans for heart failure patients. This technology is important for proactive management, early intervention, and continuous monitoring, which can help prevent hospitalizations and reduce healthcare costs.
Daxor (Nasdaq: DXR) has been awarded a $1.9 million two-year contract from the U.S. Air Force (USAF) to support the development of a next-generation point-of-care blood volume analyzer. This marks Daxor's third consecutive contract with the USAF, focusing on creating a novel fluorescent tracer and optical sensing technology for both military and civilian applications.
The funding comes through the USAF's Tactical Funding Increase (TACFI) Program of AFWERX, aimed at fostering innovation and rapid development of affordable technologies. Daxor's blood volume analysis (BVA) diagnostic is designed to improve decision-making in fluid resuscitation and blood transfusions, potentially enhancing patient survival rates and outcomes in combat casualty care and civilian settings.
Daxor (Nasdaq: DXR) announces the expansion of its blood volume analysis (BVA) technology to three new facilities. The company's ezBVA lab service, a CLIA-certified facility providing next-day results, is spearheading growth and broader market adoption. Recent sales wins include:
- A leading medical center in Georgia adopting ezBVA Lab service
- A North Carolina hospital purchasing a blood volume analyzer
- A top-rated Central Florida hospital implementing ezBVA Lab service
Daxor anticipates accelerated sales growth for the rest of the year. The company's Sr. VP of Commercialization and Customer Experience, Jean Oertel, emphasized that their diagnostic solution helps healthcare facilities enhance patient care while managing expenses. The increasing adoption of Daxor's BVA technology highlights its critical impact on advancing treatment effectiveness for fluid management.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has been awarded a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This funding will support the integration of hematocrit measurement into a future generation Blood Volume Analyzer (BVA).
The upgrade aims to streamline the BVA test by eliminating the need for third-party hematocrit testing devices. This marks Daxor's eighth SBIR award, demonstrating the DHA's ongoing commitment to advancing next-generation medical technologies. The company's goal is to make blood volume measurement faster and easier in various settings, from bedside to clinical testing labs and combat zones.
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri, a 300-bed Covenant Health affiliate, and a leading South Texas teaching hospital and Level 1 trauma center. CEO Michael Feldschuh highlighted that strategic investments in sales and marketing are driving growth, with further developments expected in the year's second half.
Daxor (Nasdaq: DXR) will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22, 2024, at the Rosen Shingle Creek Resort in Orlando, Florida. The company will showcase its BVA-100™ Guided-Care technology, which provides precise blood volume analysis to improve heart failure management. Daxor claims that this technology can reduce hospital stays, 30-day readmissions, and mortality rates, potentially transforming cardiovascular care. The event offers a platform for Daxor to present evidence supporting these benefits.
Daxor (Nasdaq: DXR) has appointed Dr. John L. Jefferies as Chief Medical Officer. Dr. Jefferies, an esteemed cardiologist with extensive clinical and commercial experience, will guide Daxor's strategic and clinical affairs. His role aims to accelerate the adoption of Daxor's diagnostic solutions in clinical practice, driving growth and collaboration with healthcare professionals. Dr. Jefferies brings a robust background in heart failure, cardiomyopathies, genetics, and AI, having published over 300 peer-reviewed manuscripts and served in numerous academic and leadership roles.
Summary not available.